|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Anti-Cancer(Oncology) Agents
|
Dovitinib(TKI-258;CHIR-258)
| Catalogue No. : |
C13463 |
| Product Name: |
Dovitinib(TKI-258;CHIR-258) |
| Synonym: |
CHIR-258;TKI258;TKI-258;TKI 258;CHIR258;CHIR 258 |
| Chemical Name: |
1-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one |
| CAS No. : |
405169-16-6 |
| Structure : |
|
| Molecular Formula: |
C21H21FN6O |
| Molecular Weight: |
392.43 |
| Purity: |
>98% |
| Usage: |
Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2. Phase 4. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
